Maximizing the therapeutic potential of HSP90 inhibitors

Lisa M. Butler, Roberta Ferraldeschi, Heather K. Armstrong, Margaret M. Centenera, Paul Workman

Research output: Contribution to journalReview article

71 Citations (Scopus)

Abstract

HSP90 is required for maintaining the stability and activity of a diverse group of client proteins, including protein kinases, transcription factors, and steroid hormone receptors involved in cell signaling, proliferation, survival, oncogenesis, and cancer progression. Inhibition of HSP90 alters the HSP90-client protein complex, leading to reduced activity, misfolding, ubiquitination, and, ultimately, proteasomal degradation of client proteins. HSP90 inhibitors have demonstrated significant antitumor activity in a wide variety of preclinical models, with evidence of selectivity for cancer versus normal cells. In the clinic, however, the efficacy of this class of therapeutic agents has been relatively limited to date, with promising responses mainly observed in breast and lung cancer, but no major activity seen in other tumor types. In addition, adverse events and some significant toxicities have been documented. Key to improving these clinical outcomes is a better understanding of the cellular consequences of inhibiting HSP90 that may underlie treatment response or resistance. This review considers the recent progress that has been made in the study of HSP90 and its inhibitors and highlights new opportunities to maximize their therapeutic potential.

LanguageEnglish
Pages1445-1451
Number of pages7
JournalMolecular Cancer Research
Volume13
Issue number11
DOIs
Publication statusPublished - 1 Jan 2015

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Butler, L. M., Ferraldeschi, R., Armstrong, H. K., Centenera, M. M., & Workman, P. (2015). Maximizing the therapeutic potential of HSP90 inhibitors. Molecular Cancer Research, 13(11), 1445-1451. https://doi.org/10.1158/1541-7786.MCR-15-0234
Butler, Lisa M. ; Ferraldeschi, Roberta ; Armstrong, Heather K. ; Centenera, Margaret M. ; Workman, Paul. / Maximizing the therapeutic potential of HSP90 inhibitors. In: Molecular Cancer Research. 2015 ; Vol. 13, No. 11. pp. 1445-1451.
@article{8f8acaab896d471a9bf1351e7b885abd,
title = "Maximizing the therapeutic potential of HSP90 inhibitors",
abstract = "HSP90 is required for maintaining the stability and activity of a diverse group of client proteins, including protein kinases, transcription factors, and steroid hormone receptors involved in cell signaling, proliferation, survival, oncogenesis, and cancer progression. Inhibition of HSP90 alters the HSP90-client protein complex, leading to reduced activity, misfolding, ubiquitination, and, ultimately, proteasomal degradation of client proteins. HSP90 inhibitors have demonstrated significant antitumor activity in a wide variety of preclinical models, with evidence of selectivity for cancer versus normal cells. In the clinic, however, the efficacy of this class of therapeutic agents has been relatively limited to date, with promising responses mainly observed in breast and lung cancer, but no major activity seen in other tumor types. In addition, adverse events and some significant toxicities have been documented. Key to improving these clinical outcomes is a better understanding of the cellular consequences of inhibiting HSP90 that may underlie treatment response or resistance. This review considers the recent progress that has been made in the study of HSP90 and its inhibitors and highlights new opportunities to maximize their therapeutic potential.",
author = "Butler, {Lisa M.} and Roberta Ferraldeschi and Armstrong, {Heather K.} and Centenera, {Margaret M.} and Paul Workman",
year = "2015",
month = "1",
day = "1",
doi = "10.1158/1541-7786.MCR-15-0234",
language = "English",
volume = "13",
pages = "1445--1451",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

Butler, LM, Ferraldeschi, R, Armstrong, HK, Centenera, MM & Workman, P 2015, 'Maximizing the therapeutic potential of HSP90 inhibitors', Molecular Cancer Research, vol. 13, no. 11, pp. 1445-1451. https://doi.org/10.1158/1541-7786.MCR-15-0234

Maximizing the therapeutic potential of HSP90 inhibitors. / Butler, Lisa M.; Ferraldeschi, Roberta; Armstrong, Heather K.; Centenera, Margaret M.; Workman, Paul.

In: Molecular Cancer Research, Vol. 13, No. 11, 01.01.2015, p. 1445-1451.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Maximizing the therapeutic potential of HSP90 inhibitors

AU - Butler, Lisa M.

AU - Ferraldeschi, Roberta

AU - Armstrong, Heather K.

AU - Centenera, Margaret M.

AU - Workman, Paul

PY - 2015/1/1

Y1 - 2015/1/1

N2 - HSP90 is required for maintaining the stability and activity of a diverse group of client proteins, including protein kinases, transcription factors, and steroid hormone receptors involved in cell signaling, proliferation, survival, oncogenesis, and cancer progression. Inhibition of HSP90 alters the HSP90-client protein complex, leading to reduced activity, misfolding, ubiquitination, and, ultimately, proteasomal degradation of client proteins. HSP90 inhibitors have demonstrated significant antitumor activity in a wide variety of preclinical models, with evidence of selectivity for cancer versus normal cells. In the clinic, however, the efficacy of this class of therapeutic agents has been relatively limited to date, with promising responses mainly observed in breast and lung cancer, but no major activity seen in other tumor types. In addition, adverse events and some significant toxicities have been documented. Key to improving these clinical outcomes is a better understanding of the cellular consequences of inhibiting HSP90 that may underlie treatment response or resistance. This review considers the recent progress that has been made in the study of HSP90 and its inhibitors and highlights new opportunities to maximize their therapeutic potential.

AB - HSP90 is required for maintaining the stability and activity of a diverse group of client proteins, including protein kinases, transcription factors, and steroid hormone receptors involved in cell signaling, proliferation, survival, oncogenesis, and cancer progression. Inhibition of HSP90 alters the HSP90-client protein complex, leading to reduced activity, misfolding, ubiquitination, and, ultimately, proteasomal degradation of client proteins. HSP90 inhibitors have demonstrated significant antitumor activity in a wide variety of preclinical models, with evidence of selectivity for cancer versus normal cells. In the clinic, however, the efficacy of this class of therapeutic agents has been relatively limited to date, with promising responses mainly observed in breast and lung cancer, but no major activity seen in other tumor types. In addition, adverse events and some significant toxicities have been documented. Key to improving these clinical outcomes is a better understanding of the cellular consequences of inhibiting HSP90 that may underlie treatment response or resistance. This review considers the recent progress that has been made in the study of HSP90 and its inhibitors and highlights new opportunities to maximize their therapeutic potential.

UR - http://www.scopus.com/inward/record.url?scp=84947086892&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-15-0234

DO - 10.1158/1541-7786.MCR-15-0234

M3 - Review article

VL - 13

SP - 1445

EP - 1451

JO - Molecular Cancer Research

T2 - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 11

ER -

Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P. Maximizing the therapeutic potential of HSP90 inhibitors. Molecular Cancer Research. 2015 Jan 1;13(11):1445-1451. https://doi.org/10.1158/1541-7786.MCR-15-0234